Autoimmune Diseases — Comprehensive Study Notes

Core Concept: Autoimmune Disease — A Misguided Defensive Strategy

  • Autoimmune disease (AD) = pathologic, specific adaptive immune response directed against self-antigens (autoAg)
    • Can be antibody-mediated, T-cell–mediated, or mixed
    • Root cause: loss or breakdown of immunological tolerance
  • Healthy immune system ⇒ balances
    • Recognition & rapid elimination of foreign Ag (activation / effector mechanisms)
    • Tolerance to self (no destructive response)
    • Regulatory T cells (Tregs) maintain this balance
  • In AD the balance tips → persistent inflammation & tissue damage
    • Same effector mechanisms that normally clear microbes now injure host tissues
  • > 8080 individual ADs recognised; virtually any organ or tissue can be targeted

Normal vs. Autoimmune Immune Reaction

  • Normal sequence
    • Foreign antigen invades
    • B cells → antibodies → removal of Ag → resolution
  • Autoimmune sequence
    • Self-Ag is mis-recognised as foreign
    • Antibodies (and/or autoreactive T cells) remain & continuously attack
    • Chronic inflammation becomes self-perpetuating

Fundamental Definitions & Terminology

  • AutoAg
    • Usually proteins, less often carbohydrates, lipids or nucleic acids
    • Example: DNA in SLE
  • AutoAb
    • Antibody produced against autoAg (e.g. anti-dsDNA in SLE, anti-TSHR in Graves’)
  • Autoreactive cells = B or T lymphocytes whose receptors bind autoAg
  • Autoimmune response
    • Full integrated response (autoreactive T cells, B cells, cytokines, autoAbs)
    • Failure of self/non-self discrimination

Characteristic Features of Autoimmune Diseases

  • Persistence of self-antigen and serum autoAbs
  • Deposition of AutoAb–AutoAg (immune) complexes
    • → complement fixation, local inflammation, tissue destruction
  • Cellular infiltration (lymphocytes, monocytes) in affected tissue
  • Effector mechanisms identical to those used against microbes (CTL killing, Ab-mediated opsonisation, complement, cytokine storms)
  • Clinically: classic inflammatory quartet — redness, heat, pain, swelling
  • Most ADs are chronic & self-perpetuating

Etiology (Causes & Triggers) — Multifactorial Model

1. Genetic Susceptibility
  • Positive family history ↑ risk
  • HLA associations common (e.g. HLA-DR, HLA-DQ alleles)
  • Monogenic “natural human knockouts” illustrate critical tolerance pathways
    • AIRE mutation → failed thymic negative selection → endocrine autoimmunity
    • FOXP3 mutation → defective Tregs → widespread epithelial attacks
    • CTLA-4 mutation → uncontrolled T-cell activation
2. Gender & Hormonal Influences
  • Female:Male ratio high in many ADs (e.g. 2:0.22:0.2 for Graves’)
  • Oestrogen tends to enhance, testosterone tends to suppress immunity
  • Sex hormone modulation of gene expression & cortisol levels influences disease onset/severity
3. Environmental & Lifestyle Factors
  • Drugs: procainamide → drug-induced lupus; iodine → Graves’ flare
  • Toxins: Toxic-Oil Syndrome (Spain 19811981) → pulmonary & eosinophilic disorder
  • UV exposure → SLE flares
  • Smoking → exposes alveolar basement membrane; triggers Goodpasture’s
  • Infections (molecular mimicry)
    • Streptococcal M protein ≈ cardiac myosin → rheumatic fever
4. Immune Stimulation / Dysregulation
  • Inappropriate MHC class II expression on non-APC cells (β-cells in Type I DM)
  • Pro-inflammatory cytokine milieu (IFN-γ, IL-1, TNFα) up-regulates MHC & costimulation, breaks anergy
  • Release of sequestered Ag (MBP after BBB breach → MS‐like attack)
  • Complement deficiencies (C1, C2, C4) hinder immune-complex clearance → SLE, RA

Pathogenesis — Five-Step Model

  1. Susceptibility genes⇒\text{Susceptibility genes} \Rightarrow impaired self-tolerance
  2. Environmental insult⇒\text{Environmental insult} \Rightarrow tissue injury → new self-Ag exposure
  3. Activated APCs present self-Ag to autoreactive lymphocytes
  4. Effector T cells / autoAbs mount sustained attack
  5. Tissue injury perpetuates inflammation → progressive disease

General Classification of Autoimmune Disorders

  • Organ-specific
    • Autoimmune attack restricted to one organ’s self-Ags
    • Therapy often involves hormone/functional replacement
  • Systemic (non-organ-specific)
    • Widespread autoAgs (e.g. DNA, histones) targeted → multi-organ damage
    • Therapy aimed at global immune suppression/modulation

Organ-Specific Exemplars

Graves’ Disease (Thyrotoxicosis)
  • AutoAb: anti-TSH receptor acts as agonist → thyroid hormone over-production
  • Key clinical signs: diffuse goitre, heat intolerance, anxiety, exophthalmos (GO), pretibial myxoedema (PTM)
  • Epidemiology: incidence 20−40/100,00020{-}40/100{,}000/year; women ∼2%\sim2\% vs men 0.2%0.2\%
  • Risk factors: genetics, female sex, stress, pregnancy, iodine exposure, microbiome diversity, smoking (↑ GO)
  • Diagnosis: ↓ serum TSH, ↑ free T4 + TSHR autoAb titres; thyroid uptake scan if serology negative
  • Management
    • Antithyroid drugs (methimazole, propylthiouracil)
    • Radio-iodine therapy (caution: worsens GO)
    • Thyroidectomy for large goitres / severe GO
    • GO: IV glucocorticoids → 2nd-line teprotumumab (anti-IGF1R)
  • Outlook: lack of good animal models; novel therapeutics in trial
Myasthenia Gravis (Neuromuscular Junction)
  • AutoAbs in ≈80%\approx80\%: anti-AChR; 1−10%1{-}10\% anti-MuSK; others (LRP4, agrin, ColQ, Kv1.4)
  • Pathogenesis
    • AutoAbs → complement-mediated MAC damage, blocked ACh binding, ↓ AChR clustering → muscle weakness
  • Incidence 8−108{-}10 / 10610^{6} person-years; rising prevalence (improved survival & diagnosis?)
  • Diagnosis: anti-AChR Ab testing → anti-MuSK if negative; electromyography if seronegative
  • Management
    • Symptomatic: anticholinesterases (↑ ACh) except poor response in MuSK MG
    • Immunotherapy: corticosteroids, non-steroidal immunosuppressants
    • Rescue: plasma exchange, IVIG for crises
    • Thymectomy: thymoma or anti-AChR-positive patients <6060 y with severe weakness
    • Monitor for drug toxicities (bone density, hepatitis, renal, blood counts)
  • Research: drugs targeting IgG recycling, complement, B/T-cell survival in trials

Systemic Exemplars

Multiple Sclerosis (Demyelinating CNS Disease)
  • Immune-mediated destruction of CNS myelin → plaques / scarring
  • Effectors: self-reactive T cells ± autoAbs
  • Key clinical domains
    • Central: fatigue, cognitive decline, mood disorders
    • Visual: optic neuritis, diplopia, nystagmus
    • Motor: weakness, spasticity, ataxia
    • Sensory: paraesthesia, pain
    • Speech/swallow, bowel & bladder dysfunction
  • Pathology slide: healthy myelinated axon vs demyelinated lesion
Systemic Lupus Erythematosus (Prototype Immune-Complex Vasculitis)
  • AutoAbs: anti-dsDNA (IgG), anti-histone, anti-nuclear Abs; Abs to leukocytes, RBCs, platelets & clotting factors
  • Two key facts supporting immune-complex aetiology
    1. Marked depletion of complement C3C3 & neutrophils during flares (consumption)
    2. Inherited C1/C2/C4 deficiencies ⇒ high SLE susceptibility due to impaired IC clearance

Therapeutic Approaches — Targeting Activation & Inflammation

  • Immunosuppressive drugs
    • Corticosteroids (prednisone) — broad anti-inflammatory
    • DMARDs (methotrexate) — slow disease progression
    • Calcineurin inhibitors (cyclosporine) — ↓ T-cell IL-2 production
  • Biologics
    • Anti-TNF (infliximab) → RA, Crohn’s
    • Anti-IL-6 / IL-17 → psoriasis
    • Rituximab → deplete CD20+ B cells
  • Symptomatic agents
    • NSAIDs for pain, swelling
    • Insulin for Type I DM; thyroid hormone replacement for Hashimoto’s
    • Topical agents for dermatologic ADs
  • Lifestyle & supportive
    • Diet optimization, physiotherapy, stress reduction
  • Experimental/Advanced
    • Hematopoietic stem cell transplantation
    • Tolerogenic vaccines
    • Microbiome modulation

Ethical, Philosophical & Practical Considerations

  • Balancing immune suppression vs infection/malignancy risk
  • Equity in access to expensive biologics & advanced therapies
  • Need for personalised medicine: heterogeneity in genetic/environmental drivers
  • Long-term adherence challenges; impact on quality of life (e.g. social & work limitations documented in MG)
  • Public health: smoking cessation, UV protection, infection control to mitigate triggers

Key Numerical / Statistical References (LaTeX embedded)

  • > 8080 distinct autoimmune conditions
  • Graves’ disease incidence 20−40  per  100,000  person-years20{-}40 \; \text{per} \; 100{,}000 \; \text{person-years}
  • Female GD prevalence 2%2\%; male 0.2%0.2\%
  • GO prevalence 10−16  /  10,00010{-}16 \; /\; 10{,}000; PTM 0.15/10,0000.15 / 10{,}000
  • MG incidence 8−10/1,000,0008{-}10 / 1{,}000,000 person-years; ≈80%\approx80\% anti-AChR positive
  • Complement component deficiencies C1, C2, C4 ⇒ >90%90\% SLE risk (illustrative)

Integrative Take-Home Messages

  • Autoimmunity = consequence of failed tolerance, not “hyper-immunity” per se
  • Disease expression depends on which tolerance checkpoint fails + which environmental hit occurs
  • Shared molecular pathways (MHC presentation, co-stimulation, cytokines) create opportunities for broad-spectrum therapeutics
  • However, organ-specific nuances necessitate tailored management (e.g. hormone replacement vs systemic immunosuppression)
  • Continuous research into genetics, microbiome, and novel biologics promises more precise, less toxic interventions